Icon supporting trials to bring TCM to the US

- Last updated on GMT

Tasly Pharmaceuticals is working with Icon to have its traditional Chinese medicine (TCM) approved by the US FDA.

China-based Tasly is outsourcing one of its Phase III clinical trials to Icon and using the contract research organisation (CRO) for other tasks. Icon is providing IVRS (interactive voice response systems), data management and central laboratory services to both Dantonic Phase III trials.

We look forward to working with Tasly and to helping them in their efforts to become the first provider of [a US Food and Drug Administration] approved traditional Chinese medicine​”, Malcolm Burgess, executive vice president, Icon clinical research, said.

Related topics: Clinical Development

Related news

Show more